# DIANA Clinical Validation - Quick Interview

**Doctor:** Doc PaJanel  
**Date:** March 12, 2026  
**Time:** 10-15 minutes max  
**Goal:** Get endorsement, not redesign

---

## Opening (30 seconds)

"Doc, thanks for 10 minutes. I need clinical validation for my thesis defense. 
Our diabetes screening model for postmenopausal women uses these weights:

- LDL: 2.5 (highest - atherogenic risk)
- Triglycerides: 2.0 (insulin resistance)
- Waist: 2.0 (central obesity)
- BMI: 1.5 (general obesity)
- HDL: 1.2 (protective)
- Age: 1.0 (baseline)

Just need your clinical take on whether this ordering makes sense."

---

## The 4 Questions (5-10 minutes)

### Q1: Weight Priorities (2 min)
"In Filipino postmenopausal women, is LDL appropriately weighted highest for 
cardiovascular/atherogenic risk? Or would you rank something else higher?"

> **Expected:** "LDL makes sense" or maybe "TG is also important"
> 
> **Response:** "We have TG at 2.0, equal with waist. That work?"
> 
> **Goal:** Confirmation that LDL = 2.5, TG = 2.0 is clinically sound

---

### Q2: LAP Formula (2 min)
"We use the LAP formula `(Waist - 58) × Triglycerides` as insulin resistance 
proxy. Is the 58cm baseline reasonable for your patients, or should we note 
Filipino-specific adjustment?"

> **Expected:** "58cm is fine" or "Maybe 55cm for smaller frames"
> 
> **Goal:** Document if she says 58cm is fine. If she suggests different, 
> note it as "clinical observation" but don't change (methodology frozen).

---

### Q3: Patient Communication (2 min)
"We explain predictions to patients using SHAP - basically showing which 
biomarkers drive their individual risk. Is this level of transparency 
clinically appropriate?"

> **Expected:** "Yes, patients should understand their risk factors"
> 
> **If concerns:** "What would you emphasize instead?"

---

### Q4: Overall Validity (2 min)
"Model has 72% AUC - good for screening, not diagnosis. Appropriate for 
identifying postmenopausal women who need further evaluation?"

> **Expected:** "Yes, screening doesn't need to be perfect"
> 
> **Goal:** Quote for thesis: "Clinical expert confirmed 72% AUC appropriate 
> for screening context"

---

## The Ask (1 minute)

"Doc, can I document in my thesis that you validated these weights as 
clinically reasonable for Filipino postmenopausal women?"

> **Get verbal yes**
> 
> **Get quotable sentence:** "Can you say that in a sentence I can quote?"

---

## Documentation (Fill in during/after)

### Clinical Validator
- **Name:** Doc PaJanel
- **Credentials:** [Endocrinology / Internal Medicine / etc.]
- **Years practicing:** ___
- **Institution:** ___

### Endorsements (Check what she confirmed)

- [ ] LDL 2.5 as highest priority clinically appropriate
- [ ] TG 2.0 = Waist 2.0 weighting reasonable  
- [ ] LAP formula with 58cm baseline acceptable
- [ ] SHAP explanations clinically appropriate
- [ ] 72% AUC suitable for screening tool

### Quote for Thesis

"_______________________________
_________________________________
_________________________________
_________________________________" 

— Doc PaJanel, [credentials]

---

## If She Questions Things

**If she thinks LDL shouldn't be highest:**
> "That's interesting. We based this on Tanabe 2024 for proxy identification 
> without HOMA2. Would you say our rationale is defensible even if you'd 
> weight differently?"

**If she wants major changes:**
> "I appreciate that perspective. Our methodology is locked for this study, 
> but I'll document your observation for future work. Would you still say 
> our current approach is clinically reasonable?"

---

## Post-Interview (5 minutes)

### Add to Thesis

**Chapter 3 (Methodology) - Clinical Validation:**
> Clinical validation was conducted with Dr. [Name], an endocrinologist with 
> [X] years of experience treating Filipino postmenopausal women. The feature 
> weighting scheme was reviewed and endorsed as clinically appropriate, with 
> LDL prioritized highest (2.5) for atherogenic risk identification, followed 
> by triglycerides and waist circumference (2.0 each) for insulin resistance 
> proxy, BMI (1.5) for general obesity, HDL (1.2) as protective, and age (1.0) 
> as baseline within the 45-60 cohort.

### Defense Slide
> **Clinical Validation**
> - Validated by practicing endocrinologist
> - Confirmed weight priorities clinically sound
> - 72% AUC deemed appropriate for screening
> - LAP formula accepted for insulin resistance proxy

---

*That's it. 10-15 minutes. Get the endorsement. Move on.*